| Target Price | A$5.15 |
| Price | A$4.54 |
| Potential |
13.46%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Medibank Private 2027 .
The average Medibank Private target price is A$5.15.
This is
13.46%
register free of charge
A$5.78
27.20%
register free of charge
A$4.70
3.45%
register free of charge
|
|
| A rating was issued by 13 analysts: 5 Analysts recommend Medibank Private to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medibank Private stock has an average upside potential 2027 of
13.46%
register free of charge
|
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion A$ | 8.75 | 9.79 |
| 7.27% | 11.88% | |
| EBITDA Margin | 11.85% | 8.36% |
| 16.86% | 29.44% | |
| Net Margin | 7.30% | 7.21% |
| 18.90% | 1.25% |
6 Analysts have issued a sales forecast Medibank Private 2027 . The average Medibank Private sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Medibank Private EBITDA forecast 2027. The average Medibank Private EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Medibank Private Analysts have issued a net profit forecast 2027. The average Medibank Private net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | 0.23 | 0.26 |
| 27.78% | 13.04% | |
| P/E | 17.71 | |
| EV/Sales | 1.25 |
10 Analysts have issued a Medibank Private forecast for earnings per share. The average Medibank Private EPS is
This results in the following potential growth metrics and future valuations:
Medibank Private...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 02 2026 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Jul 08 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | May 05 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | May 04 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 02 2026 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Feb 25 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 02 2026 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Jul 08 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 02 2026 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Feb 25 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


